323 related articles for article (PubMed ID: 19813043)
21. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.
Tamaki J; Iki M; Kadowaki E; Sato Y; Chiba Y; Akiba T; Matsumoto T; Nishino H; Kagamimori S; Kagawa Y; Yoneshima H;
Osteoporos Int; 2013 Mar; 24(3):887-97. PubMed ID: 22885773
[TBL] [Abstract][Full Text] [Related]
22. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.
Bruyere O; Roux C; Detilleux J; Slosman DO; Spector TD; Fardellone P; Brixen K; Devogelaer JP; Diaz-Curiel M; Albanese C; Kaufman JM; Pors-Nielsen S; Reginster JY
J Clin Endocrinol Metab; 2007 Aug; 92(8):3076-81. PubMed ID: 17566094
[TBL] [Abstract][Full Text] [Related]
23. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
24. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
25. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
[TBL] [Abstract][Full Text] [Related]
27. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
[TBL] [Abstract][Full Text] [Related]
28. Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.
Bayhan I; Dogan NU; Ozaksit G; Uygur D; Ugurlu N; Ugur M
J Reprod Med; 2013; 58(7-8):319-23. PubMed ID: 23947082
[TBL] [Abstract][Full Text] [Related]
29. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
30. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
Liu JM; Wai-Chee Kung A; Pheng CS; Zhu HM; Zhang ZL; Wu YY; Xu L; Meng XW; Huang ML; Chung LP; Hussain NH; Sufian SS; Chen JL
Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
[TBL] [Abstract][Full Text] [Related]
32. Strontium ranelate decreases the incidence of new caudal vertebral fractures in a growing mouse model with spontaneous fractures by improving bone microarchitecture.
Geoffroy V; Chappard D; Marty C; Libouban H; Ostertag A; Lalande A; de Vernejoul MC
Osteoporos Int; 2011 Jan; 22(1):289-97. PubMed ID: 20204596
[TBL] [Abstract][Full Text] [Related]
33. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
Leslie WD; Martineau P; Bryanton M; Lix LM
Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
[TBL] [Abstract][Full Text] [Related]
34. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis.
Marie PJ; Felsenberg D; Brandi ML
Osteoporos Int; 2011 Jun; 22(6):1659-67. PubMed ID: 20812008
[TBL] [Abstract][Full Text] [Related]
35. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.
Hwang JS; Chen JF; Yang TS; Wu DJ; Tsai KS; Ho C; Wu CH; Su SL; Wang CJ; Tu ST
Calcif Tissue Int; 2008 Nov; 83(5):308-14. PubMed ID: 18843436
[TBL] [Abstract][Full Text] [Related]
36. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus.
Jiajue R; Jiang Y; Wang O; Li M; Xing X; Cui L; Yin J; Xu L; Xia W
Osteoporos Int; 2014 Aug; 25(8):1999-2005. PubMed ID: 24760246
[TBL] [Abstract][Full Text] [Related]
37. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis.
Marquis P; Roux C; de la Loge C; Diaz-Curiel M; Cormier C; Isaia G; Badurski J; Wark J; Meunier PJ
Osteoporos Int; 2008 Apr; 19(4):503-10. PubMed ID: 17929073
[TBL] [Abstract][Full Text] [Related]
38. The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
Quesada-Gómez JM; Muschitz C; Gómez-Reino J; Greisen H; Andersen HS; Dimai HP
Osteoporos Int; 2011 Sep; 22(9):2529-37. PubMed ID: 21052638
[TBL] [Abstract][Full Text] [Related]
39. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
40. [Strontium ranelate in post-menopausal osteoporosis].
Przedlacki J
Endokrynol Pol; 2011; 62 Suppl 2():23-31. PubMed ID: 22125019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
